Law360, New York (July 19, 2012, 10:12 PM ET) -- The patents for Pfizer Inc.'s blockbuster nerve pain drug Lyrica are valid, meaning Teva Pharmaceuticals Industries Ltd., Mylan Pharmaceuticals Inc. and others can't sell their planned generic versions, a Delaware federal judge said Thursday.
U.S. District Judge Gregory M. Sleet ruled that Pfizer and Northwestern University's three patents for Lyrica were not obvious, anticipated or invalid for any other reason, and issued an injunction banning Teva, Mylan and others from marketing no-name versions of the drug before it expires in 2018.
Lyrica, which was designed to...
Judge Rules Pfizer's Lyrica Patents Are Valid
To view the full article, take a free trial now.
